ASCO Issues Updated Guideline On The Role Of Bone-Modifying Agents In The Prevention

[News]

The American Society of Clinical Oncology (ASCO) issued an update to its clinical practice guideline on the use of bone-modifying agents, in particular, osteoclast inhibitors, to prevent and treat skeletal complications from bone metastases in patients with metastatic breast cancer...

More... (http://www.medicalnewstoday.com/articles/217267.php)